EAM
AKBA icon

Eagle Asset Management’s Akebia Therapeutics AKBA Stock Holding History

Eagle Asset Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-2,824,403
Closed -$28.2M – 608
2018
Q2 		$28.2M Buy
2,824,403
+98,832
+4% +$989K 0.15% 209
2018
Q1 		$26M Buy
2,725,571
+9,404
+0.3% +$132K 0.14% 214
2017
Q4 		$40.3M Sell
2,716,167
-327,700
-11% -$5.43M 0.22% 159
2017
Q3 		$59.6M Sell
3,043,867
-481,818
-14% -$7.41M 0.34% 95
2017
Q2 		$50.7M Sell
3,525,685
-24,862
-0.7% -$315K 0.31% 113
2017
Q1 		$32.7M Buy
3,550,547
+51,190
+1% +$500K 0.21% 155
2016
Q4 		$36.4M Sell
3,499,357
-12,807
-0.4% -$110K 0.24% 133
2016
Q3 		$31.8M Sell
3,512,164
-70,897
-2% -$603K 0.22% 144
2016
Q2 		$26.8M Sell
3,583,061
-238,064
-6% -$2.08M 0.19% 164
2016
Q1 		$34.4M Sell
3,821,125
-156,769
-4% -$1.27M 0.24% 138
2015
Q4 		$51.4M Buy
3,977,894
+709,817
+22% +$7.24M 0.34% 98
2015
Q3 		$31.6M Buy
3,268,077
+834,064
+34% +$7.65M 0.22% 159
2015
Q2 		$25M Buy
2,434,013
+1,195,577
+97% +$10.2M 0.14% 192
2015
Q1 		$13.8M Buy
1,238,436
+15,805
+1% +$168K 0.08% 287
2014
Q4 		$14.2M Buy
1,222,631
+783,610
+178% +$11.2M 0.08% 277
2014
Q3 		$9.71M Buy
+439,021
New +$10.1M 0.06% 327

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Eagle Asset Management's AKBA Position: Q3 2018 in Review

Eagle Asset Management sold out of Akebia Therapeutics (AKBA) in Q3 2018, closing a stake of 2,824,403 shares — an estimated $28.2M sold.

Eagle Asset Management first reported a position in AKBA in Q3 2014 and held it in 16 quarters. The position peaked at $59.6M in Q3 2017. 130 funds tracked by Wall St. Rank hold AKBA as of Q3 2018.

  • Eagle Asset Management reported no remaining Akebia Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Eagle Asset Management sold 2,824,403 Akebia Therapeutics shares in Q3 2018, an estimated $28.2M.
  • Eagle Asset Management first reported a position in Akebia Therapeutics in Q3 2014 and held it in 16 quarters.
  • Eagle Asset Management's Akebia Therapeutics position peaked at $59.6M in Q3 2017.
  • 130 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2018.

Based on Eagle Asset Management's 13F filing for Q3 2018, filed 8 Nov 2018.